top of page
CELLTIUM PRECISION PLATFORM AI ML Drug Discovery

CELLTIUM is developing precision therapeutics for CMT1A and related rare neurological disorders.

CELLTIUM TECHNOLOGY IMAGE_4.png

Powered by PRECISION™

CELLTIUM’s proprietary PRECISION™ platform translates biological insight into targeted, disease-modifying drug candidates. Combining disease-relevant models, quantitative phenotyping, multimodal data, and AI/ML-driven analytics, the platform accelerates target discovery and lead development.

Precision Pipeline

CELLTIUM’s precision pipeline addresses the core biology of CMT1A and related rare neurological disorders. Its goal is to move beyond symptom management toward therapies designed to preserve or restore peripheral nerve function.

CELLTIUM PRECISION PLATFORM

Partner With CELLTIUM

CELLTIUM welcomes strategic partnerships with biopharma companies, investors, and patient advocacy organizations to advance the CMT1A pipeline and extend the reach of the PRECISION™ platform across rare neurology.

© 2026 CELLTIUM

bottom of page